Literature DB >> 17067198

Building bridges between academic research and policy formulation: the PRUFE framework - an integral part of Ontario's evidence-based HTPA process.

Ron Goeree1, Leslie Levin.   

Abstract

Healthcare expenditure in Ontario has been escalating at increasing rates and a growing proportion of this has come from medical devices and other technologies. A comprehensive evidence-based process for the assessment of new health technologies in Ontario was recently established (the Health Technology Policy Analysis [HTPA] process). Requests for funding for new technologies are directed through a department of the Ministry called the Medical Advisory Secretariat (MAS) who, using a systematic and evidence-based approach, provides information on the safety, effectiveness, and cost effectiveness of the technology to the Ontario Health Technology Advisory Committee (OHTAC). If the OHTAC determines that the evidentiary base for making recommendations is too uncertain, a request is made to reduce this uncertainty through the conduct of a 'real world' Ontario-based study. The Program for Assessment of Technology in Health (PATH) reduction of Uncertainty through Field Evaluation (PRUFE) framework is an iterative process for collecting new information, updating prior knowledge and providing new 'real world' evidence back to the Ministry regarding the cost effectiveness of new health technologies. MAS/OHTAC has undertaken evidence-based analyses for >50 new technologies. The PRUFE framework has been successful for reducing uncertainty and controlling healthcare expenditures while providing access and improving patient outcomes.

Entities:  

Mesh:

Year:  2006        PMID: 17067198     DOI: 10.2165/00019053-200624110-00010

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  9 in total

1.  Drug eluting stents: managing coronary artery stenosis following PTCA.

Authors:  Kirsten Garces
Journal:  Issues Emerg Health Technol       Date:  2002-10

2.  Grading quality of evidence and strength of recommendations.

Authors:  David Atkins; Dana Best; Peter A Briss; Martin Eccles; Yngve Falck-Ytter; Signe Flottorp; Gordon H Guyatt; Robin T Harbour; Margaret C Haugh; David Henry; Suzanne Hill; Roman Jaeschke; Gillian Leng; Alessandro Liberati; Nicola Magrini; James Mason; Philippa Middleton; Jacek Mrukowicz; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger J Schünemann; Tessa Tan-Torres Edejer; Helena Varonen; Gunn E Vist; John W Williams; Stephanie Zaza
Journal:  BMJ       Date:  2004-06-19

Review 3.  High and rising health care costs. Part 2: technologic innovation.

Authors:  Thomas Bodenheimer
Journal:  Ann Intern Med       Date:  2005-06-07       Impact factor: 25.391

4.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

5.  Restenosis after Angioplasty.

Authors:  Mehran Moussavian; Peter J. Casterella; Paul S. Teirstein
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-04

Review 6.  A systematic review and economic analysis of drug-eluting coronary stents available in Australia.

Authors:  Sarah J Lord; Kirsten Howard; Felicity Allen; Luke Marinovich; David C Burgess; Richard King; John J Atherton
Journal:  Med J Aust       Date:  2005-11-07       Impact factor: 7.738

7.  Economic evaluation of sirolimus-eluting stents.

Authors:  Fiona M Shrive; Braden J Manns; P Diane Galbraith; Merril L Knudtson; William A Ghali
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

8.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Authors:  Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

Review 9.  Using value of information analysis to prioritise health research: some lessons from recent UK experience.

Authors:  Karl P Claxton; Mark J Sculpher
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

  9 in total
  7 in total

1.  Better analysis for better decisions: facing up to the challenges.

Authors:  Michael F Drummond; Mark J Sculpher
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Building bridges between academic research and policy formulation: when costing less means costing more.

Authors:  Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Using health technology assessment to identify research gaps: an unexploited resource for increasing the value of clinical research.

Authors:  N Ann Scott; Carmen Moga; Christa Harstall; Jacques Magnan
Journal:  Healthc Policy       Date:  2008-02

4.  Comparative effectiveness research in Ontario, Canada: producing relevant and timely information for health care decision makers.

Authors:  Danielle M Whicher; Kalipso Chalkidou; Irfan A Dhalla; Leslie Levin; Sean Tunis
Journal:  Milbank Q       Date:  2009-09       Impact factor: 4.911

5.  Evidence-Based Decision Making 3: Health Technology Assessment.

Authors:  Daria O'Reilly; Richard Audas; Kaitryn Campbell; Meredith Vanstone; James M Bowen; Lisa Schwartz; Nazila Assasi; Ron Goeree
Journal:  Methods Mol Biol       Date:  2021

Review 6.  Transparency in Decision Modelling: What, Why, Who and How?

Authors:  Christopher James Sampson; Renée Arnold; Stirling Bryan; Philip Clarke; Sean Ekins; Anthony Hatswell; Neil Hawkins; Sue Langham; Deborah Marshall; Mohsen Sadatsafavi; Will Sullivan; Edward C F Wilson; Tim Wrightson
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

7.  Assessing the performance of health technology assessment (HTA) agencies: developing a multi-country, multi-stakeholder, and multi-dimensional framework to explore mechanisms of impact.

Authors:  Robyn Millar; Alec Morton; Maria Vittoria Bufali; Sven Engels; Saudamini Vishwanath Dabak; Wanrudee Isaranuwatchai; Kalipso Chalkidou; Yot Teerawattananon
Journal:  Cost Eff Resour Alloc       Date:  2021-07-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.